Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 28;12(7):1448.
doi: 10.3390/biomedicines12071448.

Advanced and Metastatic Non-Melanoma Skin Cancer: Epidemiology, Risk Factors, Clinical Features, and Treatment Options

Zoe Gabrielle Attal  1 , Walid Shalata  2 , Arina Soklakova  1 , Lena Tourkey  1 , Sondos Shalata  3 , Omar Abu Saleh  4 , Fahed Abu Salamah  5 , Ibrahim Alatawneh  5 , Alexander Yakobson  1
Affiliations
Review

Advanced and Metastatic Non-Melanoma Skin Cancer: Epidemiology, Risk Factors, Clinical Features, and Treatment Options

Zoe Gabrielle Attal et al. Biomedicines. .

Abstract

Non-melanoma skin cancers (NMSC) form the majority of skin cancers, with basal cell carcinoma (BCC) being the most common and cutaneous squamous cell carcinoma (cSCC) being second. Prolonged ultraviolet (UV) exposure, aging, male gender, and immunosuppression represent most of the causes of this category of diseases. BCCs and cSCCs both include different types of skin cancers, such as nodular or morpheaform BCC or flat cSCC. Locally advanced and metastatic NMSCs cannot be treated surgically; thus, systemic therapy (TKI and Immunotherapy) is needed. Interestingly, NMSCs are frequently linked to abnormal Hedgehog (HH) signaling which most systemic immunotherapies for these cancers are based upon. Of note, the first line therapies of BCC, sonidegib and vismodegib, are HH inhibitors. Programmed death receptor 1 antibody (PD-1) inhibitors such as cemiplimab, pembrolizumab, and nivolumab have been approved for the treatment of cSCC. Thus, this paper reviews the epidemiology, risk factors, clinical features, and treatment options for both BCC and cSCC.

Keywords: basal cell carcinoma; cemiplimab; cutaneous squamous cell carcinoma; hedgehog; nivolumab; non-melanoma skin cancers; pembrolizumab; sonidegib; vismodegib.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 3
Figure 3
Outline of the European guidelines for the main therapeutic options for cSCC [51,52]. This review focuses on systemic treatment for locally advanced and metastatic cSCC, which are considered if the tumor is inoperable or if surgery is insufficient. Within systemic treatment, there are different options, which are described in Table 2 above.
Figure 1
Figure 1
Outline of the HH signaling pathway [16]. If an Hh ligand is present, SMO is phosphorylated, and SUFU is re-activated, while GLI2 induces Hh target genes of transcription. However, if an Hh ligand is absent, GLI is phosphorylated by PKA, GSK3, and CK1, forming GLI3R (GLI repressor), thus inhibiting the Hh target genes.
Figure 2
Figure 2
Immune checkpoint inhibitors approved by the FDA. Pembrolizumab, Nivolumab, and Cemiplimab as anti-PD-1 antibodies, Ipilimumab as an anti-CTLA-4 antibody, as well as Atezolizumab, Avelumab, and Durvalumab as anti-PD-L1 antibodies [48].
See this image and copyright information in PMC

References

    1. Zhang W., Zeng W., Jiang A., He Z., Shen X., Dong X., Feng J., Lu H. Global, regional and national incidence, mortality and disability-adjusted life-years of skin cancers and trend analysis from 1990 to 2019: An analysis of the Global Burden of Disease Study 2019. Cancer Med. 2021;10:4905–4922. doi: 10.1002/cam4.4046. - DOI - PMC - PubMed
    1. Hayes R.C., Leonfellner S., Pilgrim W., Liu J., Keeling D.N. Incidence of nonmelanoma skin cancer in New Brunswick, Canada, 1992 to 2001. J. Cutan. Med. Surg. 2007;11:45–52. doi: 10.2310/7750.2007.00010. - DOI - PubMed
    1. Urban K., Mehrmal S., Uppal P., Giesey R.L., Delost G.R. The global burden of skin cancer: A longitudinal analysis from the Global Burden of Disease Study, 1990–2017. JAAD Int. 2021;2:98–108. doi: 10.1016/j.jdin.2020.10.013. - DOI - PMC - PubMed
    1. Veisani Y., Jenabi E., Khazaei S., Nematollahi S. Global incidence and mortality rates in pancreatic cancer and the association with the Human Development Index: Decomposition approach. Public Health. 2018;156:87–91. doi: 10.1016/j.puhe.2017.12.015. - DOI - PubMed
    1. Shalhout S.Z., Emerick K.S., Kaufman H.L., Miller D.M. Immunotherapy for Non-melanoma Skin Cancer. Curr. Oncol. Rep. 2021;23:125. doi: 10.1007/s11912-021-01120-z. - DOI - PMC - PubMed

LinkOut - more resources